3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
3
Recruiting
3
Completed
2
Withdrawn
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Lymphoid
7
Other hematologic neoplasm
3
Thoracic
2
Genitourinary
2
Breast
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Breast Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
1
Heart Diseases
1
Cardiotoxicity
1
Interventions
Trastuzumab
379
Paclitaxel
369
Cyclophosphamide
338
Docetaxel
314
Capecitabine
198
Doxorubicin
196
Letrozole
184
Tamoxifen
154
Carboplatin
153
Fulvestrant
136
Bevacizumab
129
Anastrozole
120
exemestane
119
Lapatinib
117
Epirubicin
116
Gemcitabine
112
Radiotherapy
107
palbociclib
94
Exercise
87
Fluorouracil
83
Vinorelbine
82
Surveys and Questionnaires
81
pertuzumab
77
Albumin-Bound Paclitaxel
76
Filgrastim
71
130-nm albumin-bound paclitaxel
64
pembrolizumab
63
Everolimus
59
Cisplatin
59
eribulin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Echocardiography
×
Breast
×
Clear all
NCT03510689
2024-10-16
Gene-HEART
Abramson Cancer Center at Penn Medicine
Completed
79 enrolled
NCT03940625
2022-05-25
ANKE
Heinrich-Heine University, Duesseldorf
Phase NA
Completed
69 enrolled